Volume | 88,523 |
|
|||||
News | - | ||||||
Day High | 0.9583 | Low High |
|||||
Day Low | 0.88 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Enveric Biosciences Inc | ENVB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.934 | 0.88 | 0.9583 | 0.90 | 0.934 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
201 | 88,523 | $ 0.9130393 | $ 80,825 | - | 0.649 - 6.98 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:25:32 | 1 | $ 0.8975 | USD |
Enveric Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.09M | 2.32M | - | 0 | -17.46M | -7.52 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Enveric Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ENVB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.94 | 0.98 | 0.8558 | 0.9045893 | 117,183 | -0.04 | -4.26% |
1 Month | 1.02 | 1.19 | 0.83 | 1.01 | 257,778 | -0.12 | -11.76% |
3 Months | 0.7197 | 2.92 | 0.649 | 1.37 | 4,713,097 | 0.1803 | 25.05% |
6 Months | 1.89 | 2.92 | 0.649 | 1.36 | 2,221,016 | -0.99 | -52.38% |
1 Year | 1.60 | 6.98 | 0.649 | 2.55 | 2,010,518 | -0.70 | -43.75% |
3 Years | 2.35 | 14.87 | 0.1551 | 2.01 | 1,687,345 | -1.45 | -61.70% |
5 Years | 6.00 | 14.87 | 0.1551 | 2.61 | 2,069,811 | -5.10 | -85.00% |
Enveric Biosciences Description
Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN). |